Biocon Limited has informed the Exchange regarding a press release dated July 29, 2021, titled "Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee�� (insulin glargine-yfgn injection) for the Treatment of Diabetes.".